Sir Jonathan Symonds is a Senior Advisor to IntraBio Inc. Sir Jonathan is the Chairman of GlaxoSmithKline. He has extensive life sciences, international finance, and governance experience.
Jon served as an Independent Non-Executive Director of HSBC Holdings plc from April 2014 and as Deputy Group Chairman from August 2018 until he retired from the Board in February 2020.
He was previously Chairman of HSBC Bank plc, Chief Financial Officer of Novartis AG, Partner and Managing Director of Goldman Sachs, Chief Financial Officer of AstraZeneca plc, and a Partner at KPMG.
His governance experience includes roles as Non-Executive Director and Chair of the Audit Committees of Diageo plc and QinetiQ Group plc and Non-Executive Chair of Proteus Digital Health Inc.
Jon is a Non-Executive Director of Rubius Therapectics, Inc; Non-Executive Director of Genomics England Limited, having previously served as its Chairman, and a Member of the European Round Table for Industry.
Alex Gorsky is the former Chairman and Chief Executive Officer at Johnson & Johnson.
Mr. Gorsky began his Johnson & Johnson career as a sales representative with Janssen Pharmaceutica in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management including assignments in the U.S., Europe, Africa and the Middle East. He progressed through many management posts at J&J, culminating in being named Chief Executive Officer on April 26, 2012 and Chairman of the Board on December 28, 2012.
Mr. Gorsky currently sits on the boards of JP Morgan, Apple, IBM and the Travis Manion Foundation, and serves on the Business Council and the Wharton School of the University of Pennsylvania Board of Advisors. He is also a former member of the Business Roundtable. He graduated from the United States Military Academy and received an M.B.A. from the Wharton School of the University of Pennsylvania.
Stephen Aselage is a Senior Advisor to IntraBio Inc. Mr. Aselage most recently served as Chief Executive Officer of Travere Therapeutics, a biopharmaceutical company specializing in identifying, developing, and delivering life-changing therapies to people living with rare diseases, which he joined in 2012. He has more than 40 years of experience in the biopharmaceutical industry, including substantial rare disease, commercial, and business development experience.
From 2005 to 2012, Mr. Aselage served as Executive Vice President and Chief Business Officer of BioMarin. Prior to BioMarin, Mr. Aselage held positions of increasing responsibility at a number of companies, including Bristol Laboratories, Genentech, and Sangstat. He served as the chairman of Acer and on the board of Travere.
He currently serves as chairman of Acuitas, as Director at BioCryst Pharmaceuticals, and on the advisory council of the University of Notre Dame Department of Science.